Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Current Deferred Revenue (2016 - 2025)

Integra Lifesciences Holdings' Current Deferred Revenue history spans 17 years, with the latest figure at $11.5 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 9.7% year-over-year to $11.5 million; the TTM value through Dec 2025 reached $11.5 million, up 9.7%, while the annual FY2025 figure was $11.5 million, 9.7% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $11.5 million at Integra Lifesciences Holdings, up from $11.3 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $16.2 million in Q3 2023 and bottomed at $5.3 million in Q4 2021.
  • The 5-year median for Current Deferred Revenue is $10.5 million (2024), against an average of $9.5 million.
  • The largest annual shift saw Current Deferred Revenue plummeted 54.97% in 2022 before it soared 153.11% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $5.3 million in 2021, then skyrocketed by 36.98% to $7.3 million in 2022, then grew by 17.74% to $8.5 million in 2023, then grew by 22.75% to $10.5 million in 2024, then rose by 9.7% to $11.5 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Current Deferred Revenue are $11.5 million (Q4 2025), $11.3 million (Q3 2025), and $11.1 million (Q2 2025).